{
    "clinical_study": {
        "@rank": "84250", 
        "brief_summary": {
            "textblock": "This study will treat patients who have a short term central catheter that is thought to be\n      infected with a specific bacteria (gram positive bacteria)"
        }, 
        "brief_title": "Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria", 
        "completion_date": {
            "#text": "July 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "Bacterial Infections", 
            "Gram-Positive Bacterial Infections", 
            "Bacteremia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacteremia", 
                "Bacterial Infections", 
                "Gram-Positive Bacterial Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a central indwelling catheter with signs and symptoms of infection\n\n        Exclusion Criteria:\n\n          -  Patients with tunneled catheter which cannot be removed.\n\n          -  Patients with evidence of endovascular infection including endocarditis.\n\n          -  Patients with infection of permanent intravascular devices.\n\n          -  Patients who have received more than 1 day of another antibiotic before enrollment.\n\n          -  Patients with HIV and low CD4 count."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "739", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 14, 2002", 
        "id_info": {
            "nct_id": "NCT00037050", 
            "org_study_id": "M12600080", 
            "secondary_id": "A5951060"
        }, 
        "intervention": [
            {
                "intervention_name": "Linezolid", 
                "intervention_type": "Drug", 
                "other_name": "Zyvox"
            }, 
            {
                "intervention_name": "Vancomycin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Oxacillin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Dicloxacillin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dicloxacillin", 
                "Oxacillin", 
                "Vancomycin", 
                "Linezolid"
            ]
        }, 
        "lastchanged_date": "September 11, 2009", 
        "link": {
            "description": "Link to FDA Alert", 
            "url": "http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm101503.htm"
        }, 
        "official_title": "Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram-Positive Bloodstream Infections", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_outcome": [
            {
                "measure": "The empiric treatment of patients with complicated skin and skin structure infections (cSSSI) related to an indwelling catheter;"
            }, 
            {
                "measure": "The empiric treatment of patients with gram-positive catheter-related bloodstream infections."
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Australia", 
                "Austria", 
                "Belgium", 
                "Brazil", 
                "Chile", 
                "Colombia", 
                "Czech Republic", 
                "France", 
                "Germany", 
                "Greece", 
                "Guatemala", 
                "Hungary", 
                "India", 
                "Ireland", 
                "Italy", 
                "Mexico", 
                "Pakistan", 
                "Panama", 
                "Peru", 
                "Philippines", 
                "Poland", 
                "Portugal", 
                "Russian Federation", 
                "Slovakia", 
                "South Africa", 
                "Spain", 
                "Thailand", 
                "Turkey", 
                "Venezuela"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037050"
        }, 
        "responsible_party": {
            "name_title": "Director, Clinical Trial Disclosure Group", 
            "organization": "Pfizer, Inc."
        }, 
        "secondary_outcome": {
            "measure": "Clinical efficacy of linezolid compared to vancomycin/oxacillin/dicloxacillin.2.Incidence of late metastatic sequelae associated with S. aureus infections in patients treated with linezolid"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2009"
    }, 
    "geocoordinates": {}
}